Pioneering Diagnostic and Therapeutic Innovations for Cancer and Infectious Diseases

At PAN Biologics, we are pioneering advanced diagnostic tools, viral therapies for infectious diseases, and therapeutic radiopharmaceuticals to target cancer with precision therapy

Contact Us

About PAN Biologics

Driving Innovation in Cancer and Antiviral Therapies

PAN Biologics is a spinout from Oak Ridge National Laboratory focused on developing first-in-class radiopharmaceuticals and biologics that target key signaling pathways driving infectious diseases and cancer. 

Our Technology

Innovative radiopharmaceuticals and viral therapies targeting cancer and infectious diseases with precision and efficacy.

Therapeutics

Selective Inhibition. Precision Delivery.

  • Payload: Actinium-225 for alpha-particle therapy.
  • Efficacy in disease resistant to current modalities.

Diagnostics

Functional oncogenic marker detection from Plasma

  • Real-time monitoring of tumor signaling dynamics.
  • Clinically actionable, minimally invasive.

Mechanism-Based Drug Screening

Accelerating Oncology Drug Development

  • Validates therapeutic impact.
  • Functional, phenotypic, and receptor-level assays.
  • Ideal for pharma & biotech partnerships.

Our Team

PAN Biologics was founded by Dr. Kuntal De, a scientist with a stellar research background from the Cleveland Clinic, The Ohio State University’s James Cancer Hospital, and Oak Ridge National Laboratory. Dr. De launched PAN Biologics to bring cutting-edge science out of the lab and into the clinic, focusing on precision therapies for infectious diseases and resistant cancers. Our team brings deep expertise in virology, oncology, molecular biology, and radiopharmaceutical development, combining academic excellence with a passion for real-world impact.

Kuntal De PhD
Kuntal De PhD CEO and Founder
Debjani Pal PhD
Debjani Pal PhD Preclinical Research Advisor – Radioisotope Crosslinking and In Vivo Models
Christopher L. Brett MD, DABR
Christopher L. Brett MD, DABR University of Tennessee Health Science Clinical Advisor
Sandra Davern PhD
Sandra Davern PhD Radiopharmaceutical Advisor – Isotope Selection and Targeted Delivery
Gregg Bostick
Gregg Bostick Director, TSBDC Business Advisor
Debasish Sen PhD
Debasish Sen PhD Drug Discovery and In Vivo Model Lead Advisor

From molecular insight to therapeutic impact.

 

Our pipeline reflects a focused effort to disrupt the oncogenic signaling axis and viral internalization through novel peptide therapeutics, nanobody constructs, and targeted delivery systems. 

Product Program Target Identification Research and development Preclinical clinical

PB001

Cancer

PB002

Cancer

PB003

Cancer

PB004

Cancer

PB005

Antiviral

News & Publication

Science-Driven and Nationally Recognized

A. “Basic to Breakthrough” research article by DOE (Department of Energy) Office of Science.

Learn More

B. Research was selected as one of the top 10 News highlights in the whole academic year 2022 and 2023 from ORNL (Nation’s largest multidisciplinary science program).

Learn More

C. How plant biology research could inform COVID-19 treatments.

Learn More

D. Government Media Spotlight: The Science Behind PAN Biologics”

Learn More

Targeted therapies for treatment-resistant non-small cell lung cancer.

Primary link

  • About Us
  • Technology
  • Team
  • Why Choose Us
  • Partners
  • News & Publication

Official Contact

  • +1-555-0123
  • info@panbiologics.com
  • 11519 Kingston Pike Farragut, TN, 37934, USA
Linkedin
  • Privacy Policies
Scroll to Top